The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.

Giorgino F, Guerci B, Füchtenbusch M, Lebrec J, Boye K, Orsini Federici M, Heitmann E, Dib A, Yu M, Sapin H, García-Pérez LE

Diabetes, obesity & metabolism12 Sept 2023Cited by 5 (Europe PMC)

PMID37700627DOI10.1111/dom.15244PepBankPUB-37700627

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyOther
In patients with type 2 diabetes, dulaglutide initiation was linked to fewer significant treatment changes than liraglutide initiation.
In plain wordsIn patients with diabetes, dulaglutide initiation was linked to fewer significant treatment changes than liraglutide initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSignificant treatment change
Study
n = 2,005
Comparator
Liraglutide
Analysis
Primary
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Significant treatment change
28.2%
Dulaglutide
Adjusted hazard ratio
0.54 ratio
Dulaglutide versus liraglutide
Significant treatment change
45.2%
Liraglutide
Source sentences
Summary
By IPTW analysis, dulaglutide-initiating patients were less likely to have a significant treatment change (hazard ratio [HR] 0.54, 95% confidence interval [CI] 0.46-0.63) and more likely to be persistent with treatment (HR 0.69, 95% CI 0.56-0.86) over 24 months than liraglutide-initiating patients.
2 context sentences(design, population, supporting numbers)
Summary · context
The 286 of 1014 patients (28.2%) in the dulaglutide cohort and 448 of 991 patients (45.2%) in the liraglutide cohort had a significant treatment change over 24 months.
Summary · context
The prospective, real-world TROPHIES study included patients with type 2 diabetes initiating their first injectable glucose-lowering medication (GLM), dulaglutide or liraglutide, in France, Germany and Italy.
Report a problemFND-3770062706
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, after adjustment, liraglutide-initiating patients were more likely to have a significant treatment change than dulaglutide-initiating patients over 24 months.
In plain wordsIn adults with type 2 diabetes, people starting liraglutide were more likely than those starting dulaglutide to change treatment within 24 months.
Peptide
Liraglutide
Outcome
IncreaseTime to first significant treatment change
Study
n = 991
Comparator
Dulaglutide
Analysis
Primary
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
hazard ratio (dulaglutide vs liraglutide)
0.54 HR
treatment change
Source sentences
Summary
By IPTW analysis, dulaglutide-initiating patients were less likely to have a significant treatment change (hazard ratio [HR] 0.54, 95% confidence interval [CI] 0.46-0.63)
2 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was the time spent on dulaglutide or liraglutide until a significant treatment change over 24 months.
Summary · context
The prospective, real-world TROPHIES study included patients with type 2 diabetes initiating their first injectable glucose-lowering medication (GLM), dulaglutide or liraglutide, in France, Germany and Italy.
Report a problemFND-3770062702
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes starting an injectable, 45.2% of the liraglutide cohort and 28.2% of the dulaglutide cohort had a significant treatment change over 24 months.
In plain wordsIn adults with type 2 diabetes, more people starting liraglutide than dulaglutide had a major treatment change within 24 months.
Peptide
Liraglutide
Outcome
Not applicableProportion with a significant treatment change over 24 months
Study
n = 991
Comparator
Dulaglutide
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
significant treatment change
45.2%
liraglutide cohort
significant treatment change
28.2%
dulaglutide cohort
Source sentences
Summary
The 286 of 1014 patients (28.2%) in the dulaglutide cohort and 448 of 991 patients (45.2%) in the liraglutide cohort had a significant treatment change over 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
The prospective, real-world TROPHIES study included patients with type 2 diabetes initiating their first injectable glucose-lowering medication (GLM), dulaglutide or liraglutide, in France, Germany and Italy.
Report a problemFND-3770062701
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, after adjustment, liraglutide-initiating patients were less likely to stay on treatment than dulaglutide-initiating patients over 24 months.
In plain wordsIn adults with type 2 diabetes, people starting liraglutide were less likely than those starting dulaglutide to stay on their treatment for 24 months.
Peptide
Liraglutide
Outcome
DecreasePersistence with treatment
Study
n = 991
Comparator
Dulaglutide
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
hazard ratio (dulaglutide vs liraglutide)
0.69 HR
persistence
Source sentences
Summary
and more likely to be persistent with treatment (HR 0.69, 95% CI 0.56-0.86)
1 context sentence(design, population, supporting numbers)
Summary · context
The prospective, real-world TROPHIES study included patients with type 2 diabetes initiating their first injectable glucose-lowering medication (GLM), dulaglutide or liraglutide, in France, Germany and Italy.
Report a problemFND-3770062703
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes starting an injectable, HbA1c fell by 11.91 mmol/mol with liraglutide over 24 months, similar to dulaglutide.
In plain wordsIn adults with type 2 diabetes, HbA1c fell with liraglutide by about the same amount as with dulaglutide over 24 months.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline to 24 months
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
HbA1c change
−11.91 mmol/mol
liraglutide, 24 months
Source sentences
Summary
Dulaglutide and liraglutide yielded similar HbA1c (-11.80 mmol/mol [1.08%] and -11.91 mmol/mol [1.09%]) and weight (-3.5 kg and -3.3 kg) reductions from baseline to 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
The prospective, real-world TROPHIES study included patients with type 2 diabetes initiating their first injectable glucose-lowering medication (GLM), dulaglutide or liraglutide, in France, Germany and Italy.
Report a problemFND-3770062704
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes starting an injectable, weight fell by 3.3 kg with liraglutide over 24 months, similar to dulaglutide.
In plain wordsIn adults with type 2 diabetes, weight fell with liraglutide by about the same amount as with dulaglutide over 24 months.
Peptide
Liraglutide
Outcome
DecreaseWeight change from baseline to 24 months
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
weight change
−3.3 kg
liraglutide, 24 months
Source sentences
Summary
Dulaglutide and liraglutide yielded similar HbA1c (-11.80 mmol/mol [1.08%] and -11.91 mmol/mol [1.09%]) and weight (-3.5 kg and -3.3 kg) reductions from baseline to 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
The prospective, real-world TROPHIES study included patients with type 2 diabetes initiating their first injectable glucose-lowering medication (GLM), dulaglutide or liraglutide, in France, Germany and Italy.
Report a problemFND-3770062705
07HumanObservational studyOther
In patients with type 2 diabetes, dulaglutide initiation was linked to greater treatment persistence than liraglutide initiation.
In plain wordsIn patients with diabetes, dulaglutide initiation was linked to greater treatment persistence than liraglutide initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseTreatment persistence
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Hazard ratio
0.69 ratio
Persistence analysis
Source sentences
Summary
By IPTW analysis, dulaglutide-initiating patients were less likely to have a significant treatment change (hazard ratio [HR] 0.54, 95% confidence interval [CI] 0.46-0.63) and more likely to be persistent with treatment (HR 0.69, 95% CI 0.56-0.86) over 24 months than liraglutide-initiating patients.
1 context sentence(design, population, supporting numbers)
Summary · context
The prospective, real-world TROPHIES study included patients with type 2 diabetes initiating their first injectable glucose-lowering medication (GLM), dulaglutide or liraglutide, in France, Germany and Italy.
Report a problemFND-3770062707
08HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, dulaglutide and liraglutide were linked to similar HbA1c reductions from baseline.
In plain wordsIn patients with diabetes, dulaglutide and liraglutide were linked to similar blood sugar reductions from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedHbA1c reduction
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
HbA1c reduction
1.08%
Dulaglutide
HbA1c change
−11.8 mmol/mol
Dulaglutide
HbA1c change
−11.91 mmol/mol
Liraglutide
HbA1c reduction
1.09%
Liraglutide
Source sentences
Summary
Dulaglutide and liraglutide yielded similar HbA1c (-11.80 mmol/mol [1.08%] and -11.91 mmol/mol [1.09%]) and weight (-3.5 kg and -3.3 kg) reductions from baseline to 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
The prospective, real-world TROPHIES study included patients with type 2 diabetes initiating their first injectable glucose-lowering medication (GLM), dulaglutide or liraglutide, in France, Germany and Italy.
Report a problemFND-3770062708
09HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, dulaglutide and liraglutide were linked to similar weight reductions from baseline.
In plain wordsIn patients with diabetes, dulaglutide and liraglutide were linked to similar weight reductions from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedWeight reduction
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Weight change
−3.5 kg
Dulaglutide
Weight change
−3.3 kg
Liraglutide
Source sentences
Summary
Dulaglutide and liraglutide yielded similar HbA1c (-11.80 mmol/mol [1.08%] and -11.91 mmol/mol [1.09%]) and weight (-3.5 kg and -3.3 kg) reductions from baseline to 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
The prospective, real-world TROPHIES study included patients with type 2 diabetes initiating their first injectable glucose-lowering medication (GLM), dulaglutide or liraglutide, in France, Germany and Italy.
Report a problemFND-3770062709

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In patients with type 2 diabetes, few changes in other glucose-lowering medication patterns occurred in both dulaglutide and liraglutide cohorts.
In plain wordsIn patients with diabetes, other diabetes medication patterns changed little in both dulaglutide and liraglutide cohorts.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedOther glucose-lowering medication patterns
Study
n: not reported in source
Comparator
Baseline
Outcome group
Patterns of use · Metabolic and weight
Source sentences
Summary
Few changes in patterns of treatment with other GLMs were observed in the two cohorts.
1 context sentence(design, population, supporting numbers)
Summary · context
The prospective, real-world TROPHIES study included patients with type 2 diabetes initiating their first injectable glucose-lowering medication (GLM), dulaglutide or liraglutide, in France, Germany and Italy.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3770062710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.

Summary

Results from this study10

Studies that did not test the peptide alone1

Version history

Subjects

Publication types

MeSH terms

Keywords